Efficacy of Xuebijing Injection (血必净注射液) on Cardiopulmonary Bypass-Associated Pulmonary Injury: A Prospective, Single-center, Randomized, Double Blinded Trial

Wei Gao; Na Li; Xiao-guang Cui

doi:10.1007/s11655-018-2933-7

Your Location：

Home >

Browse articles >

Efficacy of Xuebijing Injection (血必净注射液) on Cardiopulmonary Bypass-Associated Pulmonary Injury: A Prospective, Single-center, Randomized, Double Blinded Trial

Updated：2021-08-27

- Efficacy of Xuebijing Injection (血必净注射液) on Cardiopulmonary Bypass-Associated Pulmonary Injury: A Prospective, Single-center, Randomized, Double Blinded Trial
- Chinese Journal of Integrative Medicine Vol. 24, Issue 11, Pages: 815-821(2018)
- Affiliations：
  
  Department of Anesthesiology, the Second Affiliated Hospital of Harbin Medical University,Harbin,China
- Author bio：
- Funds：
- DOI：10.1007/s11655-018-2933-7
  CLC：
- Published：2018，
  
  Published Online：31 July 2018，
Scan for full text
Gao, W., Li, N. & Cui, Xg. Efficacy of Xuebijing Injection (血必净注射液) on Cardiopulmonary Bypass-Associated Pulmonary Injury: A Prospective, Single-center, Randomized, Double Blinded Trial., Chin. J. Integr. Med. 24, 815–821 (2018). https://doi.org/10.1007/s11655-018-2933-7

Wei Gao, Na Li, Xiao-guang Cui. Efficacy of Xuebijing Injection (血必净注射液) on Cardiopulmonary Bypass-Associated Pulmonary Injury: A Prospective, Single-center, Randomized, Double Blinded Trial. [J]. Chinese Journal of Integrative Medicine 24(11):815-821(2018)
Gao, W., Li, N. & Cui, Xg. Efficacy of Xuebijing Injection (血必净注射液) on Cardiopulmonary Bypass-Associated Pulmonary Injury: A Prospective, Single-center, Randomized, Double Blinded Trial., Chin. J. Integr. Med. 24, 815–821 (2018). https://doi.org/10.1007/s11655-018-2933-7 DOI：

Wei Gao, Na Li, Xiao-guang Cui. Efficacy of Xuebijing Injection (血必净注射液) on Cardiopulmonary Bypass-Associated Pulmonary Injury: A Prospective, Single-center, Randomized, Double Blinded Trial. [J]. Chinese Journal of Integrative Medicine 24(11):815-821(2018) DOI： 10.1007/s11655-018-2933-7.

摘要

To evaluate the efficacy of Xuebijing Injection (血必净注射液

XBJ) on the lung injury induced by cardiopulmonary bypass (CPB). Fifty patients undergoing CPB were randomized to either the saline group or XBJ group according to a random number table (25 cases in each group). The patients in the saline group received saline and patients in XBJ group received XBJ at 12 h prior to the operation

at the beginning of the operation

and at 12 h after the second injection. The PaO2/FiO2 at extubation 3 days post-operation

duration of ventilation in the intensive care unit (ICU)

and lengths of stay in the ICU and hospital were recorded. The levels of inflammatory mediators including interleukin (IL)-1β

IL-8

IL-10

and C-reactive protein (CRP) in bronchoalveolar lavage fluid (BALF) and plasma were measured. The neutrophil count and elastase neutrophil elastase in BALF were also measured. In addition

adverse events were monitored. The PaO2/FiO2 in the XBJ group was higher than that in the saline group from 12 to 72 h post-operation (all P<0.05). The blood levels of IL-1β

IL-8

and CRP in the XBJ group from 12 to 72 h were all significantly lower than those in the saline group (all P<0.05). In contrast

the level of the anti-inflammatory cytokine IL-10 was significantly higher in the XBJ group than in the saline group (P<0.05). In addition

4 patients presented with atelectasis in the saline group and none in the XBJ group. Ten patients experienced mild acute respiratory distress syndrome (ARDS) during hospitalization

and 5 patients with mild ARDS were in the XBJ group (P<0.05). XBJ shows protective potential against lung injury in patients who undergo CPB surgery

possibly through the downregulation of inflammatory mediators

reduction in neutrophil infiltration

and upregulation of IL-10 (Trial registry: ChiCTR-TRC-14004628).

Abstract

To evaluate the efficacy of Xuebijing Injection (血必净注射液

at the beginning of the operation

and at 12 h after the second injection. The PaO2/FiO2 at extubation 3 days post-operation

duration of ventilation in the intensive care unit (ICU)

and lengths of stay in the ICU and hospital were recorded. The levels of inflammatory mediators including interleukin (IL)-1β

IL-8

IL-10

and C-reactive protein (CRP) in bronchoalveolar lavage fluid (BALF) and plasma were measured. The neutrophil count and elastase neutrophil elastase in BALF were also measured. In addition

adverse events were monitored. The PaO2/FiO2 in the XBJ group was higher than that in the saline group from 12 to 72 h post-operation (all P<0.05). The blood levels of IL-1β

IL-8

and CRP in the XBJ group from 12 to 72 h were all significantly lower than those in the saline group (all P<0.05). In contrast

the level of the anti-inflammatory cytokine IL-10 was significantly higher in the XBJ group than in the saline group (P<0.05). In addition

4 patients presented with atelectasis in the saline group and none in the XBJ group. Ten patients experienced mild acute respiratory distress syndrome (ARDS) during hospitalization

and 5 patients with mild ARDS were in the XBJ group (P<0.05). XBJ shows protective potential against lung injury in patients who undergo CPB surgery

possibly through the downregulation of inflammatory mediators

reduction in neutrophil infiltration

and upregulation of IL-10 (Trial registry: ChiCTR-TRC-14004628).

关键词

Xuebijing Injectioncardiopulmonary bypasslung injuryinflammationrandomized controlled trial

Keywords

Xuebijing Injectioncardiopulmonary bypasslung injuryinflammationrandomized controlled trial

references

Morariu AM, Loef BG, Aarts LP, Rietman GW, Rakhorst G, van Oevere W, et al. Dexamethasone: benefit and prejudice for patients undergoing on-pump coronary artery bypass grafting: a study on myocardial, pulmonary, renal, intestinal, and hepatic injury. Chest 2005;128:2677–2687.

Apostolakis E, Filos KS, Koletsis E, Dougenis D. Lung dysfunction following cardiopulmonary bypass. J Card Surg 2010;25:47–55.

Xing Z, Han J, Hao X, Wang J, Jiang C, Hao Y, et al. Immature monocytes contribute to cardiopulmonary bypassinduced acute lung injury by generating inflammatory descendants. Thorax 2017;72:245–255.

He XD, Wang Y, Wu Q, Wang HX, Chen ZD, Zheng RS, et al. Xuebijing protects rats from sepsis challenged with acinetobacter baumannii by promoting annexin α1 expression and inhibiting proinflammatory cytokines secretion. Evid Based Complement Alternat Med 2013;2013:804940.

Sun J, Xue Q, Guo L, Cui L, Wang J. Xuebijing protects against lipopolysaccharide-induced lung injury in rabbits. Exp Lung Res 2010;36:211–218.

Li D, Lu L, Zhang J, Wang X, Xing Y, Wu H, et al. Mitigating the effects of Xuebijing Injection on hematopoietic cell injury induced by total body irradiation with gamma rays by decreasing reactive oxygen species levels. Int J Mol Sci 2014;15:10541–10553.

Zhang SK, Zhuo YZ, Li CX, Yang l, Gao Hw, Wang XM. Xuebijing Injection and resolvin D1 synergize regulate leukocyte adhesion and improve survival rate in mice with sepsis-induced lung injury. Chin J Integr Med 2018;24:272–277.

Yin Q, Li C. Treatment effects of Xuebijing Injection in severe septic patients with disseminated intravascular coagulation. Evid-Based Complement Alternat Med 2014;2014:949254.

Qi F, Liang ZX, She DY, Yan GT, Chen LA. A clinical study on the effects and mechanism of Xuebijing Injection in severe pneumonia patients. J Tradit Chin Med 2011;31:46–49.

Dai YL, Li JY, Bai HY, Liu S, Dou YQ, Hu S. Xuebijing Injection increases early survival rate by alleviating pulmonary vasopermeability in rats subjected to severe burns. Chin J Integr Med 2017;23:703–708.

Kim JC, Shim JK, Lee S, Yoo YC, Yang SY, Kwak YL. Effect of combined remote ischemic preconditioning and postconditioning on pulmonary function in valvular heart surgery. Chest 2012;142:467–475.

French JK, White HD. Clinical implications of the new definition of myocardial infarction. Heart 2004;90:99–106.

Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31.

Zhou X, Jiang R, Dong Y, Wang L. Remote ischemic preconditioning attenuates cardiopulmonary bypassinduced lung injury. PLoS One 2017;12:e0189501.

Engels GE, Dodonov M, Rakhorst G, van Oeveren W, Milano AD, Gu YJ, et al. The effect of pulsatile cardiopulmonary bypass on lung function in elderly patients. Int J Artif Organs 2014;37:679–687.

Oliver WC, Nuttall GA, Orszulak TA, Bamlet WR, Abel MD, Ereth MH, et al. Hemofiltration but not steroids results in earlier tracheal extubation following cardiopulmonary bypass: a prospective, randomized double-blind trial. J Am Soc Anesthesiol 2004;101:327–339–327–339.

Chi D, Chen C, Shi Y, Wang W, Ma Y, Zhou R, et al. Ventilation during cardiopulmonary bypass for prevention of respiratory insufficiency: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 2017;96:e6454.

Clarizia NA, Manlhiot C, Schwartz SM, Sivarajan VB, Maratta R, Holtby HM, et al. Improved outcomes associated with intraoperative steroid use in high-risk pediatric cardiac surgery. Ann Thorac Surg 2011;91:1222–1227.

Biro E, van den Goor JM, de Mol BA, Schaap MC, Ko LY, Sturk A, et al. Complement activation on the surface of cell-derived microparticles during cardiac surgery with cardiopulmonary bypass-is retransfusion of pericardial blood harmful? Perfusion 2011;26:21–29.

Pang XY, Fang CC, Chen YY, Liu K, Song GM. Effects of ulinastatin on perioperative inflammatory response and pulmonary function in cardiopulmonary bypass patients. Am J Ther 2016;23:e1680–e1689.

Celik JB, Gormus N, Okesli S, Gormus ZI, Solak H. Methylprednisolone prevents inflammatory reaction occurring during cardiopulmonary bypass: effects on TNFalpha, IL–6, IL–8, IL–10. Perfusion 2004;19:185–191.

Lucas R, Verin AD, Black SM, Catravas JD. Regulators of endothelial and epithelial barrier integrity and function in acute lung injury. Biochem Pharmacol 2009;77:1763–1772.

Bhatia M, Moochhala S. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. J Pathol 2004;202:145–156.

Goodman RB, Pugin J, Lee JS, Matthay MA. Cytokinemediated inflammation in acute lung injury. Cytokine Growth Factor Rev 2003;14:523–535.

Dunican AL, Leuenroth SJ, Grutkoski P, Ayala A, Simms HH. TNFalpha-induced suppression of PMN apoptosis is mediated through interleukin-8 production. Shock 2000;14:284–288.

Jiang M, Zhou M, Han Y, Xing L, Zhao H, Dong L, et al. Identification of NF-kappaB inhibitors in Xuebijing Injection for sepsis treatment based on bioactivity–integrated UPLC–Q/TOF. J Ethnopharmacol 2013;147:426–433.

Li X, Wang X, Li S, Yan J, Li D. Diagnostic value of procalcitonin on early postoperative infection after pediatric cardiac surgery. Pediatr Crit Care Med 2017;18:420–428.

Fransen E, Maessen J, Dentener M, Senden N, Geskes G, Buurman W. Systemic inflammation present in patients undergoing CABG without extracorporeal circulation. Chest 1998;113:1290–1295.

Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363–369.

Palmerini T, Marzocchi A, Marrozzini C, Ortolani P, Saia F, Bacchi-Reggiani L, et al. Preprocedural levels of C-reactive protein and leukocyte counts predict 9–month mortality after coronary angioplasty for the treatment of unprotected left main coronary artery stenosis. Circulation 2005;112:2332–2338.

Kotani N, Hashimoto H, Sessler DI, Muraoka M, Wang JS, O’Connor MF, et al. Cardiopulmonary bypass produces greater pulmonary than systemic proinflammatory cytokines. Anesth Analg 2000;90:1039–1045.

FULL TEXT LINK

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Xuebijing Injection (血必净注射液) and Resolvin D1 Synergize Regulate Leukocyte Adhesion and Improve Survival Rate in Mice with Sepsis-Induced Lung Injury

Endorsement of CONSORT by Chinese medical journals: A survey of “instruction to authors”

A randomized controlled trial of adjunctive Bunchang Naoxintong Capsule (步长脑心通胶囊) versus maintenance dose clopidogrel in patients with CYP2C19*2 polymorphism

Astragalus membranaceus Injection combined with conventional treatment for viral myocarditis: A systematic review of randomized controlled trials

Effect of Xuebijing injection (血必净注射液) on systemic lupus erythematosus in mice

Related Author

No data

Related Institution

Department of Cell and Molecular Biology, Institute of Acute Abdominal Diseases of Intergrated Traditional Chinese and Western Medicine, Tianjin Nankai Hospital

Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women’s Hospital, Harvard Medical School

Department of Surgery, Tianjin Nankai Hospital

Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine

First Hospital Affiliated to Tianjin University of Traditional Chinese Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰